On Thursday, Walgreens Boots Alliance (NASDAQ:WBA) received a reiterated Sector Perform rating with a steady price target of $22.00 from RBC Capital. The company reported its fiscal third-quarter 2024 earnings, which fell short of expectations due to continued consumer weakness and pharmacy margin pressures. This was somewhat balanced by strong international performance and a positive EBITDA contribution from U.S. Healthcare.
Walgreens management has revised its adjusted earnings per share (EPS) guidance downward by $0.40 at the midpoint, a 12% reduction, primarily due to poorer than anticipated consumer performance and ongoing pharmacy challenges. In an effort to address these issues, the company has provided updates on its strategic review, which includes optimizing store operations, enhancing the U.S. Retail Pharmacy customer experience, integrating pharmacy and healthcare services, and streamlining the U.S. Healthcare portfolio. Further details on the implementation of these strategies are expected to be shared in today's earnings call.
The company posted an adjusted EPS of $0.63, which was below both the $0.70 estimate by RBC Capital and the $0.68 consensus. This shortfall was attributed to weaker U.S. Retail trends and sustained pressure on pharmacy margins. Compared to the same quarter last year, the quarter's results received significantly less benefit from sale-leaseback transactions, which explained 65% of the year-over-year decline in adjusted EPS.
Walgreens saw a 2.6% year-over-year increase in consolidated revenue, reaching $36.4 billion, which was slightly above the $36.2 billion estimate and the $36.0 billion consensus. The quarter's cash flow from operations was $605 million with free cash flow (FCF) of $334 million, marking an improvement of $778 million from the third quarter of fiscal year 2023, largely due to working capital optimizations and reduced capital expenditures.
Following the earnings announcement, management has adjusted the full-year 2024 EPS guidance to a range of $2.80 to $2.95, down from the previous forecast of $3.20 to $3.50.
In other recent news, law firms involved in the opioid crisis litigation have been awarded a $2.13 billion legal fee pool, with Motley Rice receiving the largest portion of $396 million. The implicated parties in the settlements include Johnson & Johnson, AbbVie (NYSE:ABBV), Teva Pharmaceutical Industries (NYSE:TEVA), and CVS, among others. The total financial impact of opioid settlements now surpasses $50 billion.
Meanwhile, AbbVie's arthritis medication, Humira, retains over 80% of its patient base despite competition from nine biosimilar drugs. In other developments, CVS Health Corp (NYSE:CVS) is seeking a private equity partner to support the expansion of Oak Street Health, a primary care provider it acquired last year. The company plans to nearly double the size of Oak Street Health to 300 clinics by 2026.
In financial news, CVS Health's first-quarter earnings for 2024 fell short of market expectations, leading to a downward revision in its guidance and a cut in its stock price target by an Argus analyst. The company now projects its adjusted operating income for 2024 to be at least $14.75 billion. However, CVS Health remains committed to margin improvement. On a different note, an analyst from TD Cowen downgraded CVS Health Corp's stock status from "Buy" to "Hold", citing potential risks and uncertainties that emerged in the first quarter. The analyst also expressed caution regarding CVS's longer-term prospects.
InvestingPro Insights
As Walgreens Boots Alliance (NASDAQ:WBA) navigates through its current challenges, a look at CVS Health Corporation (NYSE:CVS), a key player in the same industry, may provide valuable insights. CVS's aggressive share buyback strategy and its trading at a low P/E ratio relative to near-term earnings growth suggest a proactive approach to enhancing shareholder value. With a market capitalization of $76.11 billion and a P/E ratio of 10.6, CVS stands out for its financial prudence. Moreover, a robust revenue growth of 9.02% in the last twelve months as of Q1 2024 underscores its capacity to expand amidst market pressures.
InvestingPro Tips highlight CVS's prominence in the Healthcare Providers & Services industry and its consistent dividend payments for 54 consecutive years, reflecting a commitment to returning value to investors. Additionally, CVS's valuation implies a strong free cash flow yield, which is a critical metric for assessing the company's financial health and operational efficiency. For more comprehensive analysis and additional InvestingPro Tips, interested readers can explore InvestingPro's platform, where 9 more tips are available. To benefit from these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.